JGO Annual Report 2017

We are glad to present the 2017 Annual Report of JGO here. JGO has made some progress in 2017. There were 142 articles published in JGO. The total citation of JGO has increased to 3,174 and the retrieval of the journal in PubMed was impressive, with a total of 560,009 times. More information is shown in the Annual Report.

We also would like to give our sincere thanks to all our editorial board members, reviewers, authors and readers. Wish you a happy, healthy and productive 2018!

Adjuvant chemotherapy and outcomes in esophageal carcinoma

Figure 2 Overall Survival and recurrence free survival comparisons for the propensity score matched cohort. (A) OS comparison for the propensity score matched cohort. The median OS was 2.7 years (CI, 1.6–3.7) in the group that received adjuvant chemotherapy and 2.8 years (CI, 2.0–3.6) in the group that did not receive any postoperative therapy (P=0.421)...

The International Duration Evaluation of Adjuvant Chemotherapy study: implications for clinical practice

Table 1 Randomized phase III trials that constitute the IDEA project

After long anticipation, the preliminary results of the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) study were reported at the American Society of Clinical Oncology on June 4, 2017.

This issue is organized into four sections: (I) Evolution In Cancer Treatment: Adding Genomics to Histology; (II) Biologics in Various GI Malignancies; (III) Challenges in Biologics; (IV) Ongoing Perspectives and Clinical Trials. It is dedicated to providing readers with an updated and concise overview of novel biologics that are being developed or tested in various GI cancer types. Efforts toward the molecular classification for each GI cancer type will be discussed, and expert insight into the challenges of precision oncology including treatment resistance, side effects and cost-effectiveness will be presented.

Contrast-enhanced CT of the abdomen in the portal venous phase demonstrating a large heterogeneously enhancing mass in the right hepatic lobe (arrow in A) in patient 1 prior to radiation lobectomy. Two months following RL, the lesion is smaller and necrotic without evidence of internal enhancement (arrow in B). Note FLR hypertrophy (star) and decreased volume of the right hepatic lobe (arrowhead).

Optimizing the management of hepatobiliary neoplasms: a multidisciplinary and molecular challenge by Dr. Jimmy Hwang

In this issue of Journal of Gastrointestinal Oncology (JGO), a variety of comprehensive reviews highlight the multidisciplinary advancements and efforts required for optimizing care for patients with hepatobiliary neoplasms. This series, written by experts from a variety of oncologic specialties, highlights the imperative of coordinated multidisciplinary efforts both in the clinic and, most importantly, in future research endeavors that incorporate the growing body of molecular, technical, and pharmacologic advances.